Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Zomedica Q3 2026 Results: Net Loss of $3.17M, Loss Narrows

Zomedica Corp. reported net revenue of $9.9 million for the third quarter of 2026, a 22% increase compared to the same period in 2025. The company significantly reduced its net loss to $11.5 million for the first nine months of 2026, down from a $77.3 million loss in the prior year which was impacted by a large impairment expense.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue9.98.1
Gross profit6.05.4
Profit before tax-3.2-6.1
Net income-3.2-6.1
EPS (diluted, $ a share)$0.00$-0.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+22.3%
Gross margin61.1%
Operating margin-34.6%
Source

10-Q filed with the SEC, OTC: ZOMDF. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Zomedica Corp.: key numbers

Share price
$0.0910Close, Nov 16
Market cap
$89.2M
Shares outstanding
979.95MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Zomedica Corp.

All →
4:20 PM ET 8-K
Financial Results

Zomedica Financial Results

Zomedica reported record third-quarter revenue of $9.9 million, a 22% increase year-over-year, driven by strong demand for its PulseVet and Assisi therapeutic devices. The company significantly reduced its net loss by 48% and improved its cash burn by 32% to $3.2 million, marking its lowest third-quarter cash consumption on record.

Term
Q3 2026

“Zomedica delivered record third quarter revenue, continued year-over-year growth across our business, and made further progress in managing and improving upon operating costs and cash consumption.”

Larry Heaton, Chief Executive Officer of Zomedica

“Our results reflect sustained demand for our PulseVet® and Assisi® therapeutic device products, increasing adoption of our diagnostic offerings, and contributions from our Development Services segment.”

Larry Heaton, Chief Executive Officer of Zomedica

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.